An open-label safety and tolerability clinical trial of PST-611 in dry age-related macular degeneration.

2024-519025-37-00 Protocol PST-611-CT1 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 19 Jun 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 2 sites · Protocol PST-611-CT1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 12
Countries 1
Sites 2

Dry age-related macular degeneration.

Key facts

Sponsor
PulseSight Therapeutics
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Eye Diseases [C11]
Trial duration
19 Jun 2025 → ongoing
Decision date (initial)
2025-05-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Dry age-related macular degeneration.

VersionLevelCodeTermSystem organ class
27.0 PT 10075567 Dry age-related macular degeneration 100000004853

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

PulseSight Therapeutics

Sponsor organisation
PulseSight Therapeutics
Address
Biopark Batiment B, 11 Rue Watt 11 Rue Watt
City
Paris
Postcode
75013
Country
France

Scientific contact point

Organisation
PulseSight Therapeutics
Contact name
Thierry Bordet

Public contact point

Organisation
PulseSight Therapeutics
Contact name
Thierry Bordet

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 12 2
Rest of world 0

Investigational sites

France

2 sites · Ongoing, recruitment ended
CHU Grenoble Alpes - Hôpital Michallon
Ophtalmologie, Boulevard de la Chantourne, 38700, La Tronche
Assistance Publique Hopitaux de Paris – Hopital Cochin
Ophtalmologie, 27 Rue du Faubourg Saint-Jacques, 75014, Paris

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-06-19 2025-06-23 2026-01-29

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Corrective measures 1 · Art. 77 CTR

Corrective measure CM-FR-0001

Member state
France
Publication date
2025-12-15
Type
4
Reason
7
Immediate action required
No
Justification
Please refer to the attached document.

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-12-04 France Acceptable
2025-05-12
2025-05-12
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-06-19 France Acceptable
2025-05-12
2025-06-19
3 SUBSTANTIAL MODIFICATION SM-1 2026-02-26 France Acceptable
2026-03-16
2026-03-16
4 NON SUBSTANTIAL MODIFICATION NSM-2 2026-03-31 France Acceptable
2026-03-16
2026-03-31